Five drug companies including NewLink Genetics (NLNK), Juno Therapeutics (JUNO) and Intrexon (XON) reported quarterly results after the close on Monday, but some investors seemed to be more focused on the companies’ development updates than their actual earnings. Depomed Misses Depomed (DEPO) widened its loss to an adjusted 13 cents a share from last year’s 1-cent loss. Analysts were expecting earnings of a penny. Revenue fell 58% to $32.2
Earnings season is winding down, but there are still top stocks due to report, including drug giant Actavis (ACT), one of several drug stocks reporting earnings that day, including Intrexon (XON), Impax Laboratories (IPXL) and Juno Therapeutics (JUNO). Actavis is on the IBD 50 list of the very best stocks. Three other IBD 50 stocks — Regeneron Pharmaceuticals (REGN), Monster Beverage (MNST) and Autohome (ATHM) dished out results in the latest
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to 46.86 in afternoon trading in the stock market today. The stock had been declining through March before bouncing off its 50-day line late last week. Under the deal, Merck KGaA — a separate company